Jagsonpal Pharmaceuticals share news, announcements and annual reports
NSE: JAGSNPHARMBSE: 507789Pharmaceuticals & BiotechnologySmall Cap
Jagsonpal Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1987 on BSE, Mar 2000 on NSE
Last close ₹216.09down ₹5.85 (2.64%)BSE ₹216.90
Share price at the NSE close on 30 Oct 2026. Previous close ₹221.94.
30 Oct: open ₹222.00, high ₹226.64, low ₹212.58
52-week range of traded prices to 30 Oct 2026
₹155.00Low, 22 Jan 2026₹264.50High, 30 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,427 Cr1,360th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 31.38
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 5.93
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.85%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 71,54749.3% delivered
Jagsonpal Pharmaceuticals share news and announcements
550 announcements, routine notices left out, newest first. Page 5 of 11.
Jul 2023
25 Jul · Board meeting
May 2023
24 May · Disclosure
23 May · Dividend
23 May · Results
Feb 2023
8 Feb · Results
8 Feb · Board meeting
Jan 2023
31 Jan · Board meeting
Dec 2022
Nov 2022
24 Nov · Related Party Transaction
Oct 2022
Sep 2022
19 Sep · Disclosure
15 Sep · Meeting
15 Sep · Legal
Exchange has sought clarification from Jagsonpal Pharmaceuticals Limited with respect to announcement dated 15-Sep-2022 informing about Annual General Meeting.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Brief details of items deliberated and results thereof; The response of the company is awaited.15 Sep · Meeting
Aug 2022
23 Aug · Meeting
10 Aug · Legal
Exchange has sought clarification from Jagsonpal Pharmaceuticals Limited with respect to announcement dated 16-Jul-2022 informing about Appointment of Statutory Auditor.On the basis of aforesaid announcement, the Company is required to provide/clarify the following:Change in directors, key managerial personnel (Managing Director, Chief Executive Officer, Chief Financial Officer, Company Secretary etc.), Auditor and Compliance Officer: 1. Brief profile (in case of appointment) The response of the company is awaited.
Jul 2022
16 Jul · General updates
Jun 2022
30 Jun · General updates
18 Jun · Extra Ordinary Meeting
14 Jun · Related Party Transaction
May 2022
31 May · Results
31 May · General updates